Ovid and Takeda's epilepsy drug gets new life at Perceptive-backed NewCo
Perceptive Advisors is launching a NewCo around soticlestat, Ovid Therapeutics and Takeda's failed epilepsy drug, with up to $294.5 million in milestones owed to Ovid.
Ovid Therapeutics
Ovid Therapeutics is a clinical-stage neurology biotech focused on developing treatments for rare epilepsies and seizure-related disorders. The soticlestat program is being spun out into a Perceptive Advisors-backed NewCo with Takeda.